BRAF突变儿童高级别胶质瘤的一线分子靶向治疗
该回顾性多机构研究纳入19例BRAF突变儿童高级别胶质瘤患者,在初始治疗中即使用超适应症BRAF±MEK抑制剂。中位随访2.3年时,3年无进展生存率和总生存率分别为65%和82%,优于历史对照队列,且多数患者耐受良好、无4-5级毒性。
要点
- 19例BRAF突变儿童高级别胶质瘤患者一线接受BRAF±MEK抑制剂治疗。
- 中位随访2.3年,3年无进展生存率65%、总生存率82%,优于历史对照。
- 多数患者长期治疗耐受良好,未观察到4-5级毒性。
核心结论
- 对BRAF突变儿童高级别胶质瘤患者,一线靶向治疗可行且有效,临床结局优于历史数据。
- 该治疗范式目前正在儿童肿瘤协作组ACNS1723临床试验中进行前瞻性评估。
研究设计与样本
- 回顾性、多机构综述,纳入19例在初始治疗中接受超适应症BRAF±MEK抑制剂的BRAF突变儿童高级别胶质瘤患者。
- 患者中位年龄11.7岁(范围2.3-21.4岁)。
主要发现
- 组织学诊断包括高级别胶质瘤(n=6)、胶质母细胞瘤(n=3)、间变性神经节胶质瘤(n=4)、弥漫性中线胶质瘤(n=3)、高级别神经上皮肿瘤(n=1)、间变性星形细胞瘤(n=1)和间变性星形母细胞瘤(n=1)。
- 8例接受BRAF抑制剂单药治疗,11例接受BRAF与MEK抑制剂联合治疗。
- 多数患者长期治疗耐受良好,未出现4-5级毒性。
- 在可测量病灶患者中,多数观察到客观且持久的影像学缓解。
- 中位随访2.3年(范围0.3-6.5年)时,队列3年无进展生存率为65%、总生存率为82%,优于接受传统治疗的BRAF突变儿童高级别胶质瘤历史对照队列。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prognosis for patients with pediatric high-grade glioma (pHGG) is poor despite aggressive multimodal therapy. Objective responses to targeted therapy with BRAF inhibitors have been reported in some patients with recurrent BRAF-mutant pHGG but are rarely sustained. METHODS: We performed a retrospective, multi-institutional review of patients with BRAF-mutant pHGG treated with off-label BRAF +/- MEK inhibitors as part of their initial therapy. RESULTS: Nineteen patients were identified, with a median age of 11.7 years (range, 2.3-21.4). Histologic diagnoses included HGG (n = 6), glioblastoma (n = 3), anaplastic ganglioglioma (n = 4), diffuse midline glioma (n = 3), high-grade neuroepithelial tumor (n = 1), anaplastic astrocytoma (n = 1), and anaplastic astroblastoma (n = 1). Recurrent concomitant oncogenic alterations included CDKN2A/B loss, H3 K27M, as well as mutations in ATRX, EGFR, and TERT. Eight patients received BRAF inhibitor monotherapy. Eleven patients received combination therapy with BRAF and MEK inhibitors. Most patients tolerated long-term treatment well with no grade 4-5 toxicities. Objective and durable imaging responses were seen in the majority of patients with measurable disease. At a median follow-up of 2.3 years (range, 0.3-6.5), three-year progression-free and overall survival for the cohort were 65% and 82%, respectively, and superior to a historical control cohort of BRAF-mutant pHGG patients treated with conventional therapies. CONCLUSIONS: Upfront targeted therapy for patients with BRAF-mutant pHGG is feasible and effective, with superior clinical outcomes compared to historical data. This promising treatment paradigm is currently being evaluated prospectively in the Children's Oncology Group ACNS1723 clinical trial.
引用
- Rosenberg T, Yeo KK, Mauguen A, et al. Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma. Neuro Oncol. 2022. PMID: 35397478. doi:10.1093/neuonc/noac096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。